Welcome to my Blog.... Mesothelioma

Abdominal Mesothelioma, Mesothelioma, Mesothelioma diagnosis, Mesothelioma Lawyer

==============================================================================

Saturday, March 8, 2008

Fwd: U.S. cancer deaths take turn upward



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: U.S. cancer deaths take turn upward
To: mesothelioma77@gmail.com


After two straight years of historic decline, the number of cancer deaths in the United States increased in 2005, a new study shows.

Wed, 20 Feb 2008 04:51:27 GMT


Source: http://www.jsonline.com/story/index.aspx?id=720003
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: [A 23-year delayed locoregional recurrence of breast carcinoma following mastectomy.]



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [A 23-year delayed locoregional recurrence of breast carcinoma following mastectomy.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 323-6
Ogo E, Etou H, Suzuki G, Suefuji H, Tsuji C, Hattori C, Hayabuchi N

A 77-year-old woman who underwent a right modified radical mastectomy 23 years ago with no further adjuvant treatment presented with a right chest wall mass (3x4x2 cm) at the scar. She had no symptoms nor metastasis. The laboratory data were normal including tumor marker. The mass was diagnosed as compatible with a local recurrence tumor from the previous breast cancer on the ultrasonography and chest CT. After obtaining her informed consent for the therapy, we performed 60 Gy/30 fr radiotherapy on the recurrent tumor on her right chest wall with concurrent oral chemo-endocrine therapy. The first regimens were tamoxifen 20 mg/day and 5'-DFUR 600 mg/day, followed by tore- mifene 80 mg/day and 5'-DFUR 600 mg/day, and then the tumor disappeared. But three years later, we found tumor regrowth. We changed the regimen, giving 5'-DFUR 1,200 mg/day and cyclophosphamide 100 mg/day for 2 weeks followed by a 1-week drug-free period, then added 10 Gy/5 fr radiotherapy and hyperthermia twice a week. Final regimens were anastrozole 1 mg/day and capecitabine 900 mg/day. The recurrent tumor decreased and the disease stabilized. After these therapies, she had very good quality of life. We recommend radiation and/or hyperthermia with concurrent oral chemo-endocrine therapy as useful for the delayed recurrence of elderly breast cancer after a modified radical mastectomy.



___
Source: http://www.hubmed.org/display.cgi?uids=18281775
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The good, bad of hormone replacement



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 7:36 AM
Subject: The good, bad of hormone replacement
To: mesothelioma77@gmail.com


In 1996, The Women's Health Initiative began to assess the risks and benefits of conventional hormone replacement therapy.

Tue, 19 Feb 2008 08:00:00 GMT


Source: http://www.citizen-times.com/apps/pbcs.dll/article?AID=200880218081
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Teachers warn of asbestos danger (ITN via Yahoo! UK & Ireland News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Teachers warn of asbestos danger (ITN via Yahoo! UK & Ireland News)
To: mesothelioma77@gmail.com


Embargoed to 1830 Friday February 15

Fri, 15 Feb 2008 21:20:13 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12rmpva17/*http%3A//uk.news.yahoo.com/itn/20080215/tuk-teachers-warn-of-asbestos-danger-dba1618.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Personalized systemic treatment for breast cancer patients: is it a reality?



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Personalized systemic treatment for breast cancer patients: is it a reality?
To: mesothelioma77@gmail.com


[1]Breast Cancer. 2008 Feb 15;
Shimizu C, Fujiwara Y

There is a clinical demand for tools that could distinguish patients who may benefit or suffer from particular systemic treatments. High throughput technologies such as DNA microarray are anticipated as comprehensive tools for development of accurate predictive markers of treatment outcome. Although technical and statistical problems still exist in pharmacogenomic research, rigorous efforts have been made to realize treatment individualization. Clinicians should be prepared for the future use of these new technologies in the clinic through discussion involving patients and various health-care providers.



___
Source: http://www.hubmed.org/display.cgi?uids=18274835
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: God speed Holly



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: God speed Holly
To: mesothelioma77@gmail.com


God certainly knew what he was doing when he placed Holly, the boys, and me into the Beaufort community 12 years ago.

Sat, 16 Feb 2008 15:03:33 GMT


Source: http://www2.beaufortgazette.com/story/17844#comment-42914
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Deirdre Imus: Losing Another Winnable War: "Yes We Can" Conquer Childhood Cancer (HuffingtonPost)



 


---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Deirdre Imus: Losing Another Winnable War: "Yes We Can" Conquer Childhood Cancer (HuffingtonPost)
To: mesothelioma77@gmail.com


What is causing a disturbing increase in pediatric cancer and why are we losing what numerous scientists suggest is a winnable war on cancer?

Fri, 15 Feb 2008 17:19:57 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12lk610n7/*http%3A//www.huffingtonpost.com/deirdre-imus/losing-another-winnable-w_b_86841.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Deirdre Imus: Losing Another Winnable War: "Yes We Can" Conquer Childhood Cancer (HuffingtonPost)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Deirdre Imus: Losing Another Winnable War: "Yes We Can" Conquer Childhood Cancer (HuffingtonPost)
To: mesothelioma77@gmail.com


What is causing a disturbing increase in pediatric cancer and why are we losing what numerous scientists suggest is a winnable war on cancer?

Fri, 15 Feb 2008 17:19:57 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12lk610n7/*http%3A//www.huffingtonpost.com/deirdre-imus/losing-another-winnable-w_b_86841.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

[1] <http://news.search.yahoo.com/news/rss?p=asbestos+cancer>
[2] <http://www.rssfwd.com/rssfwd/unsubscribe?id=323332&email=mesothelioma77%40gmail.com&genpass=236cacc9aaf94d409f3fa2dbdf02de99>
[3] <http://www.rssfwd.com/rssfwd/opml/mesothelioma77%40gmail.com;236cacc9aaf94d409f3fa2dbdf02de99>
[4] <http://www.rssfwd.com/>
[5] <http://www.blueskyfactory.com/>

Fwd: Burton relay's new chairwoman sets stage for long walk



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Burton relay's new chairwoman sets stage for long walk
To: mesothelioma77@gmail.com


Melani Piotrowski's grandfather, former state police Trooper Thomas McPhail, died of lung cancer eight years ago.

Sat, 16 Feb 2008 20:10:57 GMT


Source: http://blog.mlive.com/flintjournal/newsnow/2008/02/burton_relays_new_chairwoman_s.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Friday, March 7, 2008

Fwd: Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:18 AM
Subject: Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res. 2008 Feb 19; 10(1): R19
Lee E, McKean-Cowdin R, Ma H, Chen Z, Van Den Berg D, Henderson BE, Bernstein L, Ursin G

ABSTRACT: INTRODUCTION: Efforts are ongoing to determine the significance of unclassified variants (UVs) in the breast cancer susceptibility genes BRCA1/2, but no study has systematically assessed whether women carrying the suspected deleterious UVs have characteristics commonly seen among women carrying known deleterious or disease-causing mutations in BRCA1/2. METHODS: We sequenced BRCA1/2 genes in 1,469 population-based female breast cancer patients diagnosed between the ages of 20-49. We used existing literature to classify variants into known deleterious mutations, polymorphic variants, and UVs. The UVs were further classified as high or low risk based on 5 methods: allele frequency, Polyphen, sequence conservation, Grantham scores, and a combination of the Grantham score and sequence conservation. Furthermore, we examined whether patients who carry the variants classified as ahigh riska using these methods have risk characteristics similar to patients with known deleterious BRCA1/2 mutations (early age at diagnosis, family history of breast or ovarian cancer, and negative ER/PR). RESULTS: We identified 262 distinct BRCA1/2 variants, including 147 UVs, in our study population. The BRCA1 UV carriers, but not BRCA2 UV carriers, who were classified as high risk using each classification method were more similar to the deleterious mutation carriers with respect to family history than those classified as alow riska. For example, the odds ratio (OR) of having a first-degree family history for the ahigh-riska women classified using Polyphen was 3.39 (95%CI=1.16-9.94) compared to normal/polymorphic BRCA1 carriers. The corresponding OR of low-risk women was 1.53 (95%CI=1.07-2.18). The OR for high-risk women defined by allele frequency was 2.00 (95%CI=1.14-3.51), and that of alow-riska women was 1.30 (95%CI=0.87-1.93). CONCLUSIONS: The results suggest that the 5 classification methods yielded similar results. Polyphen was particularly better at isolating BRCA1 UV carriers likely to have a family history, and may therefore help to classify BRCA1 UVs. Our study suggests that these methods may not be as successful in classifying BRCA2 UVs.



___
Source: http://www.hubmed.org/display.cgi?uids=18284688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Uptake of testing for BRCA1/2 mutations in South East Scotland.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:17 AM
Subject: Uptake of testing for BRCA1/2 mutations in South East Scotland.
To: mesothelioma77@gmail.com


[1]Eur J Hum Genet. 2008 Feb 20;
Holloway SM, Bernhard B, Campbell H, Lam WW

We investigated the uptake of genetic testing by 54 families in South East Scotland with a BRCA1/2 mutation. At a median of 37 months since identification of the mutation, the overall rate of uptake of testing in 269 eligible family members was 32%. First-degree relatives were significantly (P

___
Source: http://www.hubmed.org/display.cgi?uids=18285832
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:17 AM
Subject: Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Feb 19;
Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer A, Schuh A, Yee K, Messner HA

BACKGROUND: Evaluation of therapeutic outcomes and risk factors was undertaken for patients with primary solid tumors (PST) developing acute leukemia or myelodysplasia (MDS) as a second malignancy. METHODS: In all, 131 consecutive patients presenting to a single institution with leukemia or MDS after treatment for PST with surgery or chemotherapy/radiotherapy were examined. Management of the secondary acute leukemia and MDS consisted either of intensive therapy including allogeneic blood and marrow transplants or supportive measures. RESULTS: The time from diagnosis of PST to development of acute leukemia or MDS, the cytogenetic profile of patients, and their survival were similar irrespective of PST therapy with surgery alone or strategies involving chemotherapy and/or radiation. The median survival of all 131 patients was 10.5 months with a 5-year survival of 15.6%. Induction therapy and/or transplantation resulted in a median survival of 13.6 months and a 5-year survival of 26.6% compared with 6.5 months and 2% with supportive measures. Subset analysis of transplant recipients revealed a median survival of 17.6 months and a 37.9% 5-year survival. Despite a significantly lower recurrence rate the survival of transplant recipients was not improved secondary to a higher treatment-related mortality (TRM) rate. CONCLUSIONS: Patients developing acute leukemia or MDS after PST demonstrated similar cytogenetic profiles and clinical outcomes independent of the type of treatment. Survival was significantly better for patients able to undergo intensive therapy compared with supportive measures. The low recurrence rate for allograft recipients was consistent with a potent antileukemic effect that may translate into a survival benefit if TRM could be reduced. Cancer 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18286528
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Vinny Jones R.A.C. Advert (Spoof)



---------- Forwarded message ----------
From: YouTube :: Tag // car insurance <rssfwd@rssfwd.com>
Date: Tue, Feb 26, 2008 at 4:33 AM
Subject: Vinny Jones R.A.C. Advert (Spoof)
To: Lorenz931@gmail.com


[1]

Vinny gets himself lost and breaks down in a very interesting town. Yet even with a bad temprement he manages to keep his cool.

Author: [2]kingpav
Keywords: [3]Vinny [4]Jones [5]Vinnyjones [6]crapstone [7]rac [8]r.a.c. [9]hardman [10]hard [11]man [12]england [13]place [14]breakdown [15]car [16]advert [17]insurance [18]spoof
Added: February 25, 2008


rss@youtube.com (kingpav) Mon, 25 Feb 2008 19:20:46 -0800

* Attachment, application/x-shockwave-flash: [19]Download
___
Source: http://youtube.com/?v=F3tZ3QEmZ3g
--
 Powered by [23]RssFwd, a service of [24]Blue Sky Factory, Inc

 

Thursday, March 6, 2008

Fwd: Cancer patients get new support group



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Cancer patients get new support group
To: mesothelioma77@gmail.com


Plans for a new support group for lung cancer patients in Hertsmere will be discussed at a public meeting in Borehamwood later this month.

Sat, 16 Feb 2008 14:24:08 GMT


Source: http://www.thisishertfordshire.co.uk/mostpopular.var.2047967.mostviewed.cancer_patients_get_new_support_group.php
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Options, advice often overwhelm cancer patients (USA Today)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Options, advice often overwhelm cancer patients (USA Today)
To: mesothelioma77@gmail.com


Bad advice, or just too much of it, can compound the trauma and damage done by the disease itself, cancer patients often find. Friends and relatives are important for support, but when these untrained people act as cancer coaches, they can sway people to make poor decisions about their care.

Sat, 16 Feb 2008 18:26:18 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12e98gpsj/*http%3A//www.usatoday.com/news/health/2008-02-16-cancer-coaches_N.htm?csp=34
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Hansen: Bar owner rethinks stance on smoking ban as he battles lung cancer (The Des Moines Register)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Hansen: Bar owner rethinks stance on smoking ban as he battles lung cancer (The Des Moines Register)
To: mesothelioma77@gmail.com


Ken Roush owns a blue-collar bar on East 14th Street. Kenny D's is the kind of place that closes at 2 a.m. and opens again four hours later.

Sat, 16 Feb 2008 10:18:10 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12pa58nbk/*http%3A//www.desmoinesregister.com/apps/pbcs.dll/article?AID=/20080216/NEWS03/802160329
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Researchers Use Transcriptome Analysis by 454 Sequencing to Identify Tumor Specific Mutations Linked to Malignant ... (Centre Daily Times)



---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Tue, Feb 26, 2008 at 4:17 AM
Subject: Researchers Use Transcriptome Analysis by 454 Sequencing to Identify Tumor Specific Mutations Linked to Malignant ... (Centre Daily Times)
To: collegeschoolloan@gmail.com


454 Life Sciences, a part of Roche Applied Science, today announced that researchers from The International Mesothelioma Program at Brigham and Women's Hospital and Harvard Medical School in Boston have used the 454 long-read sequencing technology to characterize for the first time mutations in expressed genes unique to malignant pleural mesotheliomas (MPMs). The 454 Sequencing system was used ...

Mon, 25 Feb 2008 22:24:02 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=124pkisas/*http%3A//www.centredaily.com/business/technology/story/425679.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Wednesday, March 5, 2008

Fwd: Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban ... (PR Newswire via Yahoo! News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Thu, Feb 28, 2008 at 2:39 PM
Subject: Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban ... (PR Newswire via Yahoo! News)
To: collegeschoolloan@gmail.com


The Mesothelioma Applied Research Foundation (Meso Foundation) is urging Members of Congress to pass Representative Betty L. McCollum's (D-Minnesota) "Bruce Vento Ban Asbestos and Prevent Mesothelioma Act" (HR 3339) and work with the Senate to get a bill to the President's desk for his signature during this Congressional session.

Thu, 28 Feb 2008 16:23:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=15eqjgb7u/*http%3A//news.yahoo.com/s/usnw/20080228/pl_usnw/leading_asbestos_cancer_group_urges_congress_to_partner_with_them_and_support_funding_provisions_in_asbestos_ban_legislation
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Carnival of Personal Finance #137 - The Passion Edition



---------- Forwarded message ----------
From: Bloglines Search: 'life insrance' <rssfwd@rssfwd.com>
Date: Thu, Feb 28, 2008 at 2:40 PM
Subject: Carnival of Personal Finance #137 - The Passion Edition
To: collegeschoolloan@gmail.com


Mrs. Micah from Mrs. Micah: Finance for a Freelance Life presents No ... from The Amatureist Financial Journey presents Biggest Insrance Scams, why

support@bloglines.com Mon, 28 Jan 2008 05:21:00 GMT

___
Source: http://feeds.feedburner.com/~r/TheDividendGuyBlog/~3/224363857/
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Ambit Biosciences Announces the Formation of Two Clinical Advisory Boards (Centre Daily Times)



---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Thu, Feb 28, 2008 at 2:39 PM
Subject: Ambit Biosciences Announces the Formation of Two Clinical Advisory Boards (Centre Daily Times)
To: collegeschoolloan@gmail.com


Ambit Biosciences today announced the formation of clinical advisory boards that will help the company advance its drug candidates in development for the treatment of blood cancers and solid tumors. The first advisory board will be focused on hematology and oncology, and the second will focus on solid tumors. The boards will guide Ambit on the development and implementation of the company's ...

Thu, 28 Feb 2008 13:27:25 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=124129b04/*http%3A//www.centredaily.com/business/technology/story/433234.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Cancer Info

Mesothelioma Cancer

 

Its transcendently common site is the pleura (outer lining of the lungs and chest cavity), but it may also occur in the peritoneum (the lining of the abdominal cavity) or the pericardium (a sac that surrounds the heart).

 Unlike lung cancer, there is no association between mesothelioma and smoking Malignancies involving mesothelial cells in these spread cavities are known as malignant mesothelioma, which may be localized or diffuse. Mesothelioma is the word used to describe a cancerous tumor that involves the mesothelial cells of an organ, often the lungs, heart, or abdominal organs.

 

In this disease, malignant cells develop in the mesothelium, a protective lining that covers transcendently of the spread's internal organs. Greatest malignant mesotheliomas set up complex karyotypes, with extensive aneuploidy and rearrangement of tons chromosomes.

 

Symptoms of mesothelioma may not appear until 20 to 50 years after exposure to asbestos. Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions.  A history of exposure to asbestos may increase clinical suspicion for mesothelioma.  A physical examination is performed, followed by chest X-ray and often lung function tests. The X-ray may reveal pleural thickening commonly seen after asbestos exposure and increases suspicion of mesothelioma.

 

If the cancer has length beyond the mesothelium to other parts of the size, symptoms may include pain, trouble swallowing, or swelling of the neck or engage.

 Tissue is removed, placed under the microscope, and a pathologist makes a definitive diagnosis, and issues a pathology report. Mesothelioma is diagnosed by pathological examination from a biopsy.

 

Symptoms of peritoneal mesothelioma include weight loss and cachexia, abdominal swelling and suffering due to ascites (a buildup of fluid in the abdominal cavity). Malignant mesothelioma has also been linked to curing radiation using thorium dioxide and zeolite, a silicate in the soil.

 Malignant mesothelioma is often just called simply Mesothelioma and is a form of lung cancer that is quite rare. 

 

Fw: Arthritis and Rheumatic Disease Q&A



----- Forwarded Message ----
From: CounsellingResource.com Search: mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, February 21, 2008 5:06:44 PM
Subject: Arthritis and Rheumatic Disease Q&A

...of certain ticks. In those cases of arthritis caused by bacteria, early diagnosis and treatment with antibiotics are crucial to get rid of the infection...



___
Source: http://counsellingresource.com/distress/chronic/arthritis/arthritis-qa.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 



Never miss a thing. Make Yahoo your homepage.

Tuesday, March 4, 2008

Fwd: XPC polymorphisms play a role in tissue-specific carcinogenesis: a meta-analysis.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:18 AM
Subject: XPC polymorphisms play a role in tissue-specific carcinogenesis: a meta-analysis.
To: mesothelioma77@gmail.com


[1]Eur J Hum Genet. 2008 Feb 20;
Francisco G, Menezes PR, Eluf-Neto J, Chammas R

XPC participates in the initial recognition of DNA damage during the DNA nucleotide excision repair process in global genomic repair. Polymorphisms in XPC gene have been analyzed in case-control studies to assess the cancer risk attributed to these variants, but results are conflicting. To clarify the impact of XPC polymorphisms in cancer risk, we performed a meta-analysis that included 33 published case-control studies. Polymorphisms analyzed were Lys939Gln and Ala499Val. The overall summary odds ratio (OR) for the associations of the 939Gln/Gln genotype with risk of cancer was 1.01 (95% confidence interval (95% CI): 0.94-1.09), but there were statistically significant associations for lung cancer, observed for the recessive genetic model (Lys/Lys+Lys/Gln vs Gln/Gln), (OR 1.30; 95% CI: 1.113-1.53), whereas for breast cancer a reduced but nonsignificant risk was observed for the same model (OR 0.87; 95% CI: 0.74-1.01). The results for Ala499Val showed a significant overall increase in cancer risk (OR 1.15; 95% CI: 1.02-1.31), and for bladder cancer in both the simple genetic model (Ala/Ala vs Val/Val) (OR 1.30; 95% CI: 1.04-1.61) and the recessive genetic model (Ala/Ala+Ala/Val vs Val/Val) (OR 1.32; 95% CI: 1.06-1.63). Our meta-analysis supports that polymorphisms in XPC may represent low-penetrance susceptibility gene variants for breast, bladder, head and neck, and lung cancer. XPC is a good candidate for large-scale epidemiological case-control studies that may lead to improvement in the management of highly prevalent cancers.European Journal of Human Genetics advance online publication, 20 February 2008; doi:10.1038/ejhg.2008.6.



___
Source: http://www.hubmed.org/display.cgi?uids=18285822
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:17 AM
Subject: Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness.
To: mesothelioma77@gmail.com


[1]J Cell Physiol. 2008 Feb 19;
Hegedüs L, Cho H, Xie X, Eliceiri GL

We are interested in two aspects of a given type of metastatic breast cancer: which potentially cancer-relevant genes are expressed and which factors determine invasiveness. Using reverse transcription real-time PCR, we detected gene expression of 26 matrix metalloproteinases (MMPs) in MDA-MB-231 breast cancer cells, including those of MMP-12, MMP-16 variant 2, MMP-19, MMP-20, MMP-21, MMP-23, MMP-24, MMP-25, MMP-25 variant 2, MMP-L1, MMP-26, MMP-27, and MMP-28, in contrast to the 13 MMPs detected until now in these cells. We found that MMP genes are expressed at widely different levels in these cells, over five orders of magnitude. After individual siRNA-induced depletions, we found that six additional species of cancer cell MMPs promote invasiveness in MDA-MB-231 cells: MMP-3, MMP-11, MMP-12, MMP-17, MMP-19, and MMP-23, thus raising the total to 12 endogenous MMPs which do so in these cells. The data support the conclusion that some cancer cell MMPs, although expressed at low levels, are needed for cancer trait in MDA-MB-231 cells, and that several endogenous MMPs play non-redundant roles in this process. The mRNA level of MMP-11, but not of other MMPs, rose substantially following individual siRNA-targeted depletion of cancer cell MMP-17 mRNA, while no MMP mRNA increased appreciably after degradation of other MMP mRNAs. This supports the conclusion that MMP-17 may be a member of an intracellular signaling pathway which downregulates MMP-11 mRNA. J. Cell. Physiol. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18286480
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Natural killer cell neoplasms.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:18 AM
Subject: Natural killer cell neoplasms.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Feb 19;
Liang X, Graham DK

Natural killer (NK) cell tumors are an uncommon and heterogeneous group of disorders. The World Health Organization (WHO) classified mature NK cell neoplasms into 2 types: 1) extranodal NK cell lymphoma, nasal type and 2) aggressive NK cell leukemia. The mature NK cell tumors are prevalent in Asia and Central and South America. These tumors show polymorphic neoplastic infiltrate with angioinvasion and/or angiodestruction, cytoplasmic azurophilic granules, CD2-positive (CD2(+))/CD3-negative (CD3(-))/cCD3epsilon(+)/CD56(+) phenotype, and strong association with Epstein-Barr virus (EBV). Loss of chromosomes 6q, 11q, 13q, and 17p are recurrent aberrations. Although blastic NK cell lymphoma, currently referred to as CD4(+)/CD56(+) hematodermic neoplasm, also was included in the NK cell lymphoma category in the WHO classification scheme, existing evidence indicates a plasmacytoid dendritic cell derivation as opposed to an NK cell origin. Recently, rare cases of CD56(+) immature lymphoid tumors have been reported in the literature. These tumors are characterized by blastic appearance, CD3(-)/CD4(-)/CD56(+)/CD13(-)/CD33(-) phenotype, T-cell receptor and immunoglobulin genes in germline configuration, and no evidence of EBV, suggesting a true immature NK cell derivation. For this article, the authors reviewed the recent concepts and progress in clinicopathologic features, pathogenesis, genetic characteristics, diagnosis, differential diagnosis, treatment approaches, and outcomes of all subtypes of NK cell neoplasms. Cancer 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18286525
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: ASBESTOS killer on the increase



----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Wednesday, February 27, 2008 7:16:11 PM
Subject: ASBESTOS killer on the increase

A SILENT killer will cause devastation in more Suffolk families than ever before this year, it has been warned today.

Wed, 27 Feb 2008 16:10:18 GMT

___
Source: http://www.eveningstar.co.uk/content/eveningstar/news/story.aspx?brand=ESTOnline&category=News&tBrand=ESTOnline&tCategory=News&itemid=IPED26%20Feb%202008%2011%3A57%3A29%3A510
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 


Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now.

Fwd: [Future directions of anticancer drug development in Japan.]



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: [Future directions of anticancer drug development in Japan.]
To: mesothelioma77@gmail.com


[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 351-60
Akaza H, Kawai K, Tsuruo T, Tsukagoshi S, Aiba K, Shimada Y, Kakeji Y, Ishikawa H, Ikeda T, Nakamura S, Tamura T, Yamamoto N, Isonishi S, Hinotsu S, Hirose M, Katsura J

At the 13th Oncology Forum, future directions of anticancer drug development in Japan were discussed. Development of anticancer drugs in the 1990s was based on the concept of total cell kill, but now development of molecular targeted drugs becomes the mainstream. Unfortunately, molecular targeted drugs and antibody agents are mostly foreign products and translational research in Japan is poor as it stands now. As future directions of anticancer drug development, international collaborative development is considered essential, but there are various obstacles to the conduct of international collaborative studies. Companies, medical institutions and regulatory agencies must make collaborative efforts to overcome these obstacles. As future development of anticancer agents in individual cancer regions in Japan is considered, gastric cancer therapy is progressing considerably with the advent of S-1 and in the future, development of multi-agent combination therapy including molecular targeted agents is expected. Much progress in colon cancer therapy has been made owing to accumulation of evidence in recent years. Multi-agent chemotherapy combined with antibody agent, which is advancing overseas, is introduced to Japan. Clinical development of combination therapy with a high therapeutic index, including compounds discovered in Japan, is expected in the future. Although conventionally hormone therapy has been considered as first-line treatment of breast cancer and used in combination with chemotherapy, with the advent of antibody agents in recent years, HER2 sensitivity has greatly affected the algorithm of treatment. Future development of molecular targeted drugs and individualised diagnosis using cDNA array, etc. are likely to advance individualisation of treatment. On the other hand, large-scale clinical trials are required to prove a small difference in adjuvant therapy, etc. and accordingly international studies are becoming indispensable. For urological cancers, molecular targeted drugs have been proved effective in renal cancer and future development of molecular targeted drugs for prostate cancer and testicular tumors is desirable. At that time, elucidation of the mechanism of action of molecular targeted drug and strategic drug development designed to increase its efficacy are expected. As a future direction of anticancer drug development, there are many cancers in whose international collaborative studies Japan can participate. Studies of prostate cancer and renal cell carcinoma can be internationalised while internationalisation of studies in ovarian and pancreatic cancers is essential. Phase III should be performed as international collaborative studies and depending on the type of cancer and drug, collaborative studies in an Asian region are effective. When participating in an international collaborative study, Japan needs to recruit subjects at a speed similar to the rest of the world, but differences in medical environment including clinical trials pose a problem. To solve this problem, it is considered effective not only to pursue the Western environment but also to improve staff such as nurses and CRC. The number of Japanese patients necessary for Phase III studies is individual developmental strategy and needs to be examined by both companies and regulatory agencies.



___
Source: http://www.hubmed.org/display.cgi?uids=18281781
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Speak Out ... Auburn's run of success vs. Alabama is ending



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Wed, Feb 20, 2008 at 4:02 AM
Subject: Speak Out ... Auburn's run of success vs. Alabama is ending
To: mesothelioma77@gmail.com


For six long, painful years, the graceless Tommy Tuberville and his merry band at Auburn have feasted on a decimated Alabama Crimson Tide football program.

Wed, 20 Feb 2008 08:21:10 GMT


Source: http://www.annistonstar.com/opinion/2008/as-letters-0220-speakout-8b19u2531.htm
--
  Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Wild Card -- Weekend



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 7:36 AM
Subject: Wild Card -- Weekend
To: mesothelioma77@gmail.com


Spokane Spokesman-Review - ... Christmas season continues to give us a look under the hood re: what it's like to work in a mid-major newsroom, including insight into what interns discuss here and the heartache a young journalist feels when he spends the day with a 2-year-old cancer ...

Fri, 15 Feb 2008 23:53:00 GMT

___
Source: http://www.spokesmanreview.com/blogs/hbo/archive.asp?mon=Dec2005
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Monday, March 3, 2008

Fwd: Implementing breast cancer decision aids in community sites: barriers and resources.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Implementing breast cancer decision aids in community sites: barriers and resources.
To: mesothelioma77@gmail.com


[1]Health Expect. 2008 Mar; 11(1): 46-53
Silvia KA, Ozanne EM, Sepucha KR

Objective To assess the feasibility of implementing four patient decision aids (PtDAs) for early stage breast cancer treatment decisions into routine clinical care in community settings. Background There is very limited information available about implementing decision aids into routine clinical practice and most of this information is based on academic centres; more information is needed about implementing them into routine clinical practice in community settings. Design Structured individual interviews. Setting and participants Providers from 12 sites, including nine community hospitals, a community oncology centre and two academic centres. Main outcome measures Usage data, barriers to and resources for implementing the PtDAs. Results Nine of the 12 sites were using the PtDAs with patients. All of the sites were lending the PtDAs to patients, usually without a formal sign-out system. The keys to successful implementation included nurses' and social workers' interest in distributing the PtDAs and the success of the lending model. Barriers that limited or prevented sites from using the PtDA included a lack of physician support, a lack of an organized system for distributing the PtDAs and nurses' perceptions about patients' attitude towards participation in decision making. Conclusions It is feasible to implement PtDAs for early stage breast cancer into routine clinical care in community settings, even with few resources available.



___
Source: http://www.hubmed.org/display.cgi?uids=18275401
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prevalence of Abdominal and Pelvic Surgeries in Patients With Irritable Bowel Syndrome: Comparison Between Caucasian and African Americans.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Prevalence of Abdominal and Pelvic Surgeries in Patients With Irritable Bowel Syndrome: Comparison Between Caucasian and African Americans.
To: mesothelioma77@gmail.com


[1]Am J Med Sci. 2008 Feb; 335(2): 82-88
Minocha A, Johnson WD, Wigington WC

BACKGROUND:: Although controversial, studies suggest that irritable bowel syndrome (IBS) is associated with an increased risk of abdominal and pelvic surgeries. However, the role of race in this interaction has not been defined. We studied the prevalence of appendectomy, cholecystectomy, and hysterectomy among African American patients with IBS among the population at large and compared it with the Caucasians residing in same area. METHODS:: A total of 990 adults from 9 different sites in the Jackson, Mississippi, metropolitan area (670 African Americans and 320 Caucasians), completed self-administered questionnaires providing sociodemographic information and details regarding bowel habits and associated symptoms for diagnosing the IBS, based on ROME II criteria. We recorded the patient's name, age, sex, race, history of smoking, and history of surgeries. Subjects with a history of IBD and gastrointestinal cancer were excluded. The prevalence of appendectomy and hysterectomy was compared between IBS patients and non-IBS control subjects. RESULTS:: One thousand ninety-nine, or 84%, of those distributed were returned. On checking the exclusion and inclusion criteria, we eliminated 109 subjects. The reasons for elimination of 109 subjects included incomplete questionnaires and incorrect marking of questionnaires that resulted in invalid data. Overall, there was significantly higher prevalence of appendectomy (15.3% vs 5.1%) and cholecystectomy (6.6% vs 3.4%) but not hysterectomy (21.1% vs 17.6%; P = NS) among Caucasian Americans as compared with African Americans. The prevalence of appendectomy among IBS patients (n = 95) versus non-IBS subjects (n = 895) was not statistically significant (10.5% vs 8.2%; OR, 1.3; 95% CI, 0.7 to 2.7; P = 0.43). The prevalence of cholecystectomy in the 2 groups was also similar (5.3% vs 4.4%). Likewise, there was no statistically significant difference for the prevalence of hysterectomy among females IBS patients versus non-IBS females (23.3% vs 18.2%; OR, 1.4; 95% CI, 0.8 to 2.4; P = 0.29). Comparing the prevalence of these surgeries in with IBS patients (African Americans versus Caucasian Americans), we found significant difference in the prevalence of appendectomy to be 1.9% vs 21.4% (P

___
Source: http://www.hubmed.org/display.cgi?uids=18277113
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: A Randomized Controlled Trial of the Effect of Aerobic Exercise Training on Feelings of Energy and Fatigue in Sedentary Young Adults with Persistent Fatigue.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: A Randomized Controlled Trial of the Effect of Aerobic Exercise Training on Feelings of Energy and Fatigue in Sedentary Young Adults with Persistent Fatigue.
To: mesothelioma77@gmail.com


[1]Psychother Psychosom. 2008 Feb 14; 77(3): 167-174
Puetz TW, Flowers SS, O'Connor PJ

Background: There is growing evidence that chronic exercise is a promising intervention for combating feelings of low energy and fatigue. Although groups with well-defined medical conditions (for example cancer and heart disease) or unexplained fatigue syndromes consistently have reported improved feelings of energy and fatigue after chronic exercise, relatively few exercise training studies have been conducted with people who report persistent fatigue yet neither have a medical condition nor reach diagnostic criteria for an unexplained fatigue syndrome. The purpose of this investigation was to use a randomized controlled design to examine the effects of 6 weeks of chronic exercise training on feelings of energy and fatigue in sedentary, healthy young adults reporting persistent fatigue. Methods: Thirty-six healthy, young adults who reported persistent feelings of fatigue were randomly assigned to a moderate-intensity exercise, low-intensity exercise or no treatment control group. Participants in each condition then visited the exercise laboratory on 18 occasions over a 6-week period. Exercise laboratory visits occurred 3 days per week. Vigor and fatigue mood state scores were obtained at the beginning of the third exercise session each week for 6 weeks. Aerobic fitness was measured before and after intervention. Results: The effect of 6 weeks of exercise training on feelings of fatigue was dependent on exercise intensity; however, the effect on feelings of energy was similar for both the low- and moderate-intensity conditions. The changes in feelings of energy and fatigue were independent of changes in aerobic fitness. Conclusions: Six weeks of low and moderate exercise training performed by sedentary adults without a well-defined medical condition or an unexplained fatigue syndrome but reporting persistent feelings of fatigue resulted in similarly beneficial effects on feelings of energy. The effects for symptoms of fatigue were moderated by exercise intensity, and the more favorable outcome was realized with low-intensity exercise. Changes in feelings of energy and fatigue following exercise training were unrelated to changes in aerobic fitness. Copyright (c) 2008 S. Karger AG, Basel.



___
Source: http://www.hubmed.org/display.cgi?uids=18277063
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res. 2008 Feb 14; 10(1): R16
Aube M, Larochelle C, Ayotte P

ABSTRACT: BACKGROUND: Estrogen and androgen signalling pathways exert opposing influences on the proliferation of mammary epithelial and hormone-dependent breast cancer cells. We previously reported that plasma concentrations of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE), the main metabolite of the insecticide DDT and a potent androgen antagonist, were associated with tumor aggressiveness in women diagnosed with breast cancer. We sought to examine the biological plausibility of this association by testing the effect of p,p'-DDE on the proliferation of CAMA-1 cells, a human breast cancer cell line that expresses the estrogen receptor alpha and the androgen receptor (AR), in the presence of physiological concentrations of estrogens and androgens in the cell culture medium. METHODS: The proliferation of CAMA-1 cells was determined in 96-well plates following a 9-day treatment with p,p'-DDE alone (0.1-10 uM) or in combination with estradiol (E2; 100 pM) and dihydrotestosterone (DHT; 100, 500 or 1000 pM). We also assessed p,p'-DDE-induced modifications in cell cycle entry and the expression of the sex-steroid dependent genes ESR1, AR, CCND1 and TFF1 (pS2) (mRNA and/or protein). RESULTS: We found that treatment with p,p'-DDE induced a dose-response increase in the proliferation of CAMA-1 cells when cultivated in the presence of physiological concentrations of estrogens and androgens, but not in the absence of sex steroids in the cell culture medium. A similar effect of p,p'-DDE was noted on the proliferation of MCF7-AR1 cells, an estrogen responsive cell line that was genetically engineered to over express the AR. DHT added together with E2 to the cell culture medium decreased the recruitment of CAMA-1 cells in the S phase and the expression of ESR1 and CCND1, by comparison with cells treated with E2 alone. These androgen-mediated effects were blocked with similar efficacy by p,p'-DDE and the potent antiandrogen hydroxyflutamide. CONCLUSIONS: Our results suggest that p,p'-DDE could increase breast cancer progression by opposing the androgen signalling pathway that inhibits growth in hormone-responsive breast cancer cells. The potential role of environmental antiandrogens in breast carcinogenesis deserves further investigations.



___
Source: http://www.hubmed.org/display.cgi?uids=18275596
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Selective estrogen receptor modulators differentially regulate Alzheimer-like changes in female 3xTg-AD mice.
To: mesothelioma77@gmail.com


[1]Endocrinology. 2008 Feb 14;
Carroll JC, Pike CJ

Estrogen-based hormone therapy (HT) in postmenopausal women may reduce the risk of Alzheimer's disease (AD), although HT remains controversial. One key concern with HT is the potential of adverse outcomes such as breast and uterine cancer. A promising strategy to maximize HT benefits and minimize HT risks is the use of selective estrogen receptor modulators (SERMs) that exert tissue-specific estrogenic effects. To begin investigating the SERM approach in reducing the risk of AD, we investigated whether AD-like neuropathology in the 3xTg-AD mouse model of AD is regulated by the SERMs propylpyrazole triol (PPT) and diarylpropionitrile (DPN) that exhibit relative specificity for estrogen receptors ERalpha and ERbeta, respectively. Consistent with our previous observations, we found that ovariectomy-induced hormone depletion in adult female 3xTg-AD mice significantly increased accumulation of beta-amyloid protein (Abeta) and decreased hippocampal-dependent behavioral performance. Treatment with 17beta-estradiol (E2) prevented the ovariectomized-induced worsening of both pathologies. PPT treatment was similar to E2 in terms of reducing Abeta accumulation in hippocampus, subiculum, and amygdala but comparatively less effective in frontal cortex. In contrast, DPN did not significantly reduce Abeta accumulation in hippocampus and subiculum, was partially effective in frontal cortex, and nearly as effective as E2 in amygdala. Furthermore, PPT but not DPN mimicked the ability of E2 to improve behavioral performance. These findings provide initial evidence of beneficial actions of SERMs in a mouse model of AD and support continued investigation of SERMs as an alternative to estrogen-based HT in reducing the risk of AD in postmenopausal women.



___
Source: http://www.hubmed.org/display.cgi?uids=18276750
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas.
To: mesothelioma77@gmail.com


[1]Mol Syst Biol. 2008; 4: 169
Mani KM, Lefebvre C, Wang K, Lim WK, Basso K, Dalla-Favera R, Califano A

The computational identification of oncogenic lesions is still a key open problem in cancer biology. Although several methods have been proposed, they fail to model how such events are mediated by the network of molecular interactions in the cell. In this paper, we introduce a systems biology approach, based on the analysis of molecular interactions that become dysregulated in specific tumor phenotypes. Such a strategy provides important insights into tumorigenesis, effectively extending and complementing existing methods. Furthermore, we show that the same approach is highly effective in identifying the targets of molecular perturbations in a human cellular context, a task virtually unaddressed by existing computational methods. To identify interactions that are dysregulated in three distinct non-Hodgkin's lymphomas and in samples perturbed with CD40 ligand, we use the B-cell interactome (BCI), a genome-wide compendium of human B-cell molecular interactions, in combination with a large set of microarray expression profiles. The method consistently ranked the known gene in the top 20 (0.3%), outperforming conventional approaches in 3 of 4 cases.



___
Source: http://www.hubmed.org/display.cgi?uids=18277385
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc